Napabucasin Inhibits Proliferation and Migration of Glioblastoma Cells (U87) by Regulating JAK2/STAT3 Signaling Pathway

Basit Öğe Kaydı
dc.authoridTuncer, Mehmet Cudi/0000-0001-7317-5467
dc.contributor.authorUnlu, Ilker
dc.contributor.authorOzdemir, Ilhan
dc.contributor.authorTuncer, Mehmet Cudi
dc.date.accessioned2025-02-22T14:08:40Z
dc.date.available2025-02-22T14:08:40Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and Objectives: Napabucasin (NP) was discovered as a natural compound that suppresses cancer stemness by inhibiting the signal transducer and activator of the transcription 3 (STAT3) signaling pathway. In this study, the anti-proliferative and apoptotic effects of NP and the chemotherapy agent doxorubicin (DX), a natural compound, on glioblastoma cells (U87) were investigated. Materials and Methods: In this study, the effects of NP and DX on cell viability on the glioblastoma U87 cell line were determined by MTT test. Expressions of Jak2/Stat3 genes were examined by qRT-PCR. Apoptosis was evaluated by Hoescht 33258 staining. Moreover, NP, its antagonistic-synergistic effects and IC50 doses of the combined treatment of DX were determined. Results: Napabucacin and doxorubicin were found to inhibit glioblastoma U87 cell proliferation. It was determined that NP applied in the range of 0.3-1 mu M and its combination with DX killed almost all of the glioblastoma cells in 48 h of application. Additionally, it was observed that Jak2/Stat3 expressions downregulated. Conclusions: These results show that NP suppresses the proliferation of glioblastoma cells. It was shown that the combination of NP and DX can prevent invasion of the U87 cell line due to its Jak2/Stat3 inhibitory effect. Since it can suppress Jak2/Stat3, an important cancer cell proliferation pathway in glioblastoma, the combination of NP and DX can be used as an alternative treatment agent. But no synergistic effect of NP and DX on the U87 cells of the glioblastoma cell line was observed.en_US
dc.identifier.doi10.3390/medicina60101715
dc.identifier.issn1010-660X
dc.identifier.issn1648-9144
dc.identifier.issue10en_US
dc.identifier.pmid39459502en_US
dc.identifier.scopus2-s2.0-85207684570en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/medicina60101715
dc.identifier.urihttps://hdl.handle.net/11468/29553
dc.identifier.volume60en_US
dc.identifier.wosWOS:001342924700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofMedicina-Lithuaniaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectglioblastoma doxorubicinen_US
dc.subjectnapabucasinen_US
dc.subjectStat3 inhibitoryen_US
dc.subjectMTTen_US
dc.titleNapabucasin Inhibits Proliferation and Migration of Glioblastoma Cells (U87) by Regulating JAK2/STAT3 Signaling Pathwayen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu